Residual coronary reserve identifies segmental viability in patients with wall motion abnormalities.
OBJECTIVE
The aim of this study was to determine whether the presence of residual coronary reserve can in itself identify viable segments.


BACKGROUND
Experimental data suggest that despite hypoperfusion at rest, viable myocardium may exhibit persistence of coronary reserve. Preliminary observations in patients show that in basally dyssynergic areas, a residual vasodilator capability is present despite hypoperfusion at rest and that a flow-mediated increase in regional wall motion identifies residual viability.


METHODS
Fourteen patients with evidence of previous myocardial infarction, infarct-related single-vessel coronary artery disease and impaired regional ventricular function at rest underwent positron emission viability imaging by fluorine-18 deoxyglucose. In addition, blood flow at rest and vasodilator capability were regionally evaluated in all patients by means of nitrogen-13 ammonia.


RESULTS
Of a total of 252 segments, 133 were dyssynergic at rest. Of these 133 segments, 60 (group 1) showed normal metabolic activity and only mild reduction in myocardial blood flow. The other 73 segments showed a marked reduction in flow; of these, 25 (group 2, viable) had persistent metabolic activity, whereas 48 (group 3, necrotic) did not. Despite similar levels of hypoperfusion at rest, group 2 segments showed a preserved coronary reserve that was virtually absent in necrotic segments (2.6 +/- 1.3 vs. 1.3 +/- 0.5, p < 0.01). This value was similar to that observed in viable group 1 segments (2.5 +/- 1.6, p = NS).


CONCLUSIONS
In addition to characterizing myocardium at risk, imaging of coronary flow at baseline and after dipyridamole by positron emission tomography provides helpful information on myocardial viability that may integrate the "static" viability information obtained with the baseline flow/metabolic approach.
Marzullo
P
P
CNR Institute of Clinical Physiology, Pisa, Italy.
Parodi
O
O
Sambuceti
G
G
Giorgetti
A
A
Picano
E
E
Gimelli
A
A
Salvadori
P
P
L'Abbate
A
A
D000368:Aged; D000641:Ammonia; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D003327:Coronary Disease / Q000175:diagnosis* / Q000503:physiopathology; D003847:Deoxyglucose / Q000031:analogs & derivatives; D004176:Dipyridamole; D004452:Echocardiography; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006321:Heart / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D009590:Nitrogen Radioisotopes; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D009590:Nitrogen Radioisotopes; D019788:Fluorodeoxyglucose F18; D004176:Dipyridamole; D000641:Ammonia; D003847:Deoxyglucose